Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring JE Antibody Levels and Immunization Strategy in Low-Prevalence Areas
NCT06678373Phase 4Active, not recruiting
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Apr 2026
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of Japanese encephalitis vaccine in Japanese encephalitis (JE) (5 arms), sponsored by Liaoning Chengda Biotechnology Co., Ltd. Primary endpoints: Assessment of JE neutralizing antibody levels, Seroconversion rate against JE and 1 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
Japanese encephalitis vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT06678373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678373.